MacroGenics Third Quarter 2024 Earnings Beats Expectations
| MGNX Stock | USD 1.58 0.04 2.60% |
Slightly above 55% of MacroGenics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding MacroGenics suggests that some traders are interested. MacroGenics' investing sentiment can be driven by a variety of factors including economic data, MacroGenics' earnings reports, geopolitical events, and overall market trends.
MacroGenics | Build AI portfolio with MacroGenics Stock |
MacroGenics Third Quarter 2024 Results Key Financial Results Revenue US110.7m up by US100.3m from...
Read at simplywall.st
 |
MacroGenics Fundamental Analysis
We analyze MacroGenics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MacroGenics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MacroGenics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
MacroGenics is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
MacroGenics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MacroGenics stock to make a market-neutral strategy. Peer analysis of MacroGenics could also be used in its relative valuation, which is a method of valuing MacroGenics by comparing valuation metrics with similar companies.
Peers
MacroGenics Related Equities
| INZY | Inozyme Pharma | 178.17 | ||||
| IPSC | Century Therapeutics | 7.69 | ||||
| PEPG | PepGen | 7.69 | ||||
| ZNTL | Zentalis Pharmaceuticals | 5.88 | ||||
| PHVS | Pharvaris | 4.09 | ||||
| CGEM | Cullinan Oncology | 3.59 | ||||
| PMVP | Pmv Pharmaceuticals | 3.57 | ||||
| GLUE | Monte Rosa | 2.84 | ||||
| EWTX | Edgewise Therapeutics | 2.28 | ||||
| DAWN | Day One | 1.46 | ||||
| TYRA | Tyra Biosciences | 1.32 | ||||
| NKTX | Nkarta | 1.16 | ||||
| SNDX | Syndax Pharmaceuticals | 1.12 | ||||
| CCCC | C4 Therapeutics | 0.73 | ||||
| KZR | Kezar Life | 0.25 | ||||
| PTGX | Protagonist Therapeutics | 0.18 | ||||
| MLYS | Mineralys Therapeutics, | 0.07 | ||||
| MOLN | Molecular Partners | 0.26 | ||||
| ANTX | AN2 Therapeutics | 1.63 |
Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.